I'm simple and do not have a scientific background
Post# of 30028
Posted On: 07/17/2014 2:36:37 PM
I'm simple and do not have a scientific background to understand all that Gerald said in his blog. I remember when he has talked about other AD diagnostic tests such as Amivid that is much more invasive (they stick something in your spin), more expensive ($3,000 dollars?), and less accurate (70 to 83% range for sensitivity and specificity) When I became familiar with the LymPro blood test I remember numbers like 91% and 92% specificity and sensitivity, and we only drew blood, we didn't put something in people's spins.
That is the simple level I understand things at. When it was presented to me in that light, it was a no brainer for me to come to the conclusion that LymPro, once commercialized, would immediately become the "Industry Standard" (over 2 or 3 years time)
I know BD did a "Validation Study" on LymPro in 2013, but I'm not sure what those results were compared to the "Pilot Test" they said they would do Q1 2014, or the larger 160 patient "Analytical Performance" Test supposed to be completed in Q2 of 2014. Those are the names of the tests that stuck in my mind which Gerald spoke to us about in the final months of 2013. Does anyone else remember them that way? Because based on what Gerald said in his blog....I can't make the connections. Even though all those tests should be completed right now, I'm not sure how to identify the results of each and compare it to the original 91% and 92% sensitivity & specificity numbers I mentioned up above. It all seems to be morphed together....blurred....so that after reading Gerald's blog....I'm still needing someone to communicate to me in a way I understand.
And really, I'm not an idiot. I'm smart. Now I'm sounding like Freddo. Could someone connect the dots for me in plain English? I still don't know if the results to be reported on July 31st will be the specificity & sensitivity numbers in the mid 90s or whether that is a goal that we'll work for once we're in our CLIA partner's lab sometime in October or November. If that is the case, this stock is going nowhere on July 31st!!
Can someone clear this up for me?
That is the simple level I understand things at. When it was presented to me in that light, it was a no brainer for me to come to the conclusion that LymPro, once commercialized, would immediately become the "Industry Standard" (over 2 or 3 years time)
I know BD did a "Validation Study" on LymPro in 2013, but I'm not sure what those results were compared to the "Pilot Test" they said they would do Q1 2014, or the larger 160 patient "Analytical Performance" Test supposed to be completed in Q2 of 2014. Those are the names of the tests that stuck in my mind which Gerald spoke to us about in the final months of 2013. Does anyone else remember them that way? Because based on what Gerald said in his blog....I can't make the connections. Even though all those tests should be completed right now, I'm not sure how to identify the results of each and compare it to the original 91% and 92% sensitivity & specificity numbers I mentioned up above. It all seems to be morphed together....blurred....so that after reading Gerald's blog....I'm still needing someone to communicate to me in a way I understand.
And really, I'm not an idiot. I'm smart. Now I'm sounding like Freddo. Could someone connect the dots for me in plain English? I still don't know if the results to be reported on July 31st will be the specificity & sensitivity numbers in the mid 90s or whether that is a goal that we'll work for once we're in our CLIA partner's lab sometime in October or November. If that is the case, this stock is going nowhere on July 31st!!
Can someone clear this up for me?
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼